Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma

NACompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 13, 2016

Primary Completion Date

October 9, 2017

Study Completion Date

October 9, 2017

Conditions
Melasma
Interventions
OTHER

Lytera 2.0

Lytera 2.0 applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.

DRUG

4% Hydroquinone Topical Cream

4% Hydroquinone Topical Cream applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.

OTHER

SkinMedica Facial Cleanser

SkinMedica facial cleanser applied to the face as directed.

OTHER

SkinMedica Rejuvenative Moisturizer

SkinMedica rejuvenative moisturizer applied to the face as directed.

OTHER

SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen

SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 sunscreen applied to the face as directed.

Trial Locations (1)

10025

Mount Sinai St. Luke's Hospital, New York

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY

NCT02977507 - Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma | Biotech Hunter | Biotech Hunter